We are working on the medical challenges developing technologies to fight cancer and infections diseases. The more promising technologies are in licensed and developed in our labs and being transformed into nano medicines.
Nanoparticle albumin-bound paclitaxel or nab-paclitaxel is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.
Is used for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.
Nanoparticles, Inject. Lyoph.Original molecule
Amphotericin B Liposome for injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion.
It is an antifungal medication used for serious fungal infections and leishmaniasis.
Liposomal Pegylated, Inject. Lyoph.Original molecule
Octreotide is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone.
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors.
PLGA microspheres, Inject. Lyoph.Original molecule
Sandostatin™Lar Depot (Novartis)
Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropinreleasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. LEUPROLIDE DEPOT is available in a prefilled dual-chamber syringe containing sterile lyophilized microspheres which, when mixed with diluent, become a suspension intended as an intramuscular injection to be given one a month (7,5mg) or each 3 months.(11,25 mg and 22,5 mg).
Leuprolide depot may be used in the treatment of hormone-responsive cancers such as prostate cancer and breast cancer. It may also be used for estrogen-dependent conditions such as endometriosis or uterine fibroids.
PLGA microspheres, Inject. Lyoph.Original molecule
Pegylated Liposomal Doxorubicin is a chemotherapy medication used to treat cancer. Our product is a pegylated (polyethylene glycol coated) liposome-encapsulated form of doxorubicin, sold as Doxil. It was developed to treat Kaposi's sarcoma, an AIDS-related cancer that causes lesions to grow under the skin, in the lining of the mouth, nose and throat, or in other organs.
It is commonly used to treat some leukemias and Hodgkin's lymphoma, as well as cancers of the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple myeloma, and others.
Liposomal Pegylated, Inject suspensionOriginal molecule
Caelyx™ (Schering Plough)
Cytarabine (Liposomal) is a sustained-release form of cytarabine. It is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an "antimetabolite. Liposomal cytarabine is used to treat lymphomatous meningitis (lymphoma found in the lining of the brain and spinal cord).
Liposomal cytarabine is used to treat lymphomatous meningitis (lymphoma found in the lining of the brain and spinal cord).
Liposomes, Inject. SuspensionOriginal molecule
Depocyt®(longer-lasting liposomal formulation) Pacira Pharma
Irinotecan Liposome is a cancer medicine that interferes with the growth and spread of cancer cells in the body; is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.
Irinotecan Liposome is thought to work by blocking the action of an enzyme in cells called topoisomerase I. Cells need this enzyme to keep their DNA in the proper shape when they are dividing. Blocking this enzyme leads to breaks in the DNA, which leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by irinotecan liposome.
Liposomes, Inject. Suspension.Original molecule
Goserelin is a man-made form of a hormone that regulates many processes in the body. Goserelin overstimulates the body's own production of certain hormones, which causes that production to shut down temporarily. Goserelin implant is used in men to treat symptoms of prostate cancer.
Goserelin acetate stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner. This causes the disruption of the endogenous hormonal feedback systems, resulting in the down-regulation of testosterone and estrogen production.
Implat Microspheres, Inject. SuspensionOriginal molecule
Zoladex Astra Zeneca
Naltrexone is a medication that stops the activity of opioids. It is primarily used in the management of alcohol dependence and opioid dependence. Naltrexone helps patients overcome opioid addiction by blocking the effects of opioid drugs. It has little effect on opioid cravings.
Naltrexone is the first and only non-addictive, once-monthly medication that, when combined with counseling, is proven to help prevent relapse to opioid dependence, after detox. Naltrexone blocks opioid receptors in the brain while you work with the psychological aspects of counseling. While oral naltrexone has a demonstrated ability to decrease alcohol reinforcement, it also has pharmacotherapeutic limitations, such as a small treatment effect size, adverse events, and plasma level fluctuations.
Microspheres, Inject. Lyoph.Original molecule
Exenatide is approved "as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a biguanide, or a combination of metformin and a sulfonylurea, but have not achieved adequate glycemic control." It has now been approved for use with thiazolidinediones such as pioglitazone.
Exenatide depot action takes place in response to food entering the small intestine. Exenatide depot responds to presence of carbohydrate, in the form of glucose, by stimulating release of insulin, inhibiting release of glucagon and slowing down emptying of the stomach. Each of these three mechanisms can help to keep blood glucose levels lower.
Microspheres, Inject Lyoph.Original molecule
Bydureon Astra Zeneca
Nanomedicine, the application of nanotechnology to medicine, enabled the development of nanoparticle therapeutic carriers. Nanox's drug carriers enhance the in-vivo efficiency of many drugs especially anti-cancer drugs. These drug carriers are passively targeted to tumour through the enhanced permeability and retention effect, so they are ideally suited for the delivery of chemotherapeutics in cancer treatment. Nanox is engaged in a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Liposomes, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development.
Our more recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In view of the increasing importance of the nanotechnology, Nanox continues to discover the Nanomedicine in order to develop nanostructures as drug carriers.
At present we are working on following applications of technology:
Liposomes are vesicular sacs similar to tiny cells, composed by durable lipid bilayer membranes that separate an internal aqueous volume from the external medium. Water-soluble drugs can be encapsulated in the internal compartments, while water-insoluble drugs can be incorporated in the hydrophobic region of the membrane.
Argentine Scientists have developed an effective drug delivery system by grafting polymer groups to the liposome surface. It is used a hydrophilic polymer, methoxypolyethylene glycol (mPEG), and the critical design features of the PEG-liposome include the following:
- Increases in vivo liposome stability, reduces MPS uptake with long plasma residence times.
- Low permeability lipid matrix and carefully selected intraliposomal aqueous composition that provides high drug loading and stable encapsulation.
- Average diameter of 100 nm: Large enough to carry a substantial drug payload, yet small enough to allow efficient extravasation through vascular endothelial defects in tumor tissues.
With Pegylated liposomes, passive tissue targeting contributes to tissue specificity of the treatment. The drug carrier accumulates in the interstitial fluid of the diseased tissue by exploiting the enhanced permeability and retention effect.
Once the liposomes have infiltrated the cancerous tissue, the subsequent release of the drug from the decomposing liposomes provides local exposure to the cytoxic agent.
The delivery of controlled release drug employs drug-encapsulating devices from which therapeutic agents may be released at controlled rates for long periods of time.
Polymeric microspheres are ideal vehicles for many controlled delivery applications due to their ability to encapsulate a variety of drugs, biocompatibility, high bioavailability and sustained drug release characteristics.
The method of producing sustained-release microspheres containing a biologically active substance from an W/O emulsion comprising an inner aqueous phase containing said biologically active substance and an external oil phase containing a biodegradable polymer, characterized in that microspheres formed on microencapsulation of said biologically active substance with said biodegradable polymer are heated at a temperature not lower than the glass transition temperature of said biodegradable polymer but not so high as to cause aggregation of the microspheres.
The Depot formulations are administered to the patient and then release their active pharmaceutical ingredient for days, weeks, or months. Depot formulations comprise biodegradable excipients, lactide/glycolide polymers, which control the rate of drug release.
The pegylation of proteins was developed for improving biomedical efficacy, physicochemical and pharmacokinetics properties, and to reduce the number of weekly injections used in the treatment.
The process takes place by a chemical reaction that joins throw a covalent union a molecule of polymer of metoxipoliethilenglicol to the recombinant protein. The high molecular weight of PEG used, allows to reach therapeutic ideal properties.
Applicability and safety of this technology have been proven by use of various PEGylated pharmaceuticals for many years. It is expected that PEGylation, as the most established technology for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein, which due to their diminished molecular size need half-life extension.
This novel technology encapsulates different drugs within Nanomicelles formed with Gangliosides GM1.
- A great depth of tissue penetration for target drugs.
- Inner lipophilic core (ceramide) while the surface is hydrophilic (sugar)
- Suitable to solubilize lipophilic drugs as Paclitaxel and also remaining stable during several dilutions.
- Less toxicity in comparison with reference nano medicines.
- Expected better efficacy.
- Ability of self-assembly.
- Extremely low critical micelle concentration.
- Smaller size in comparison with liposomes (usually within 5-15 nm).
- Spontaneous loading of hydrophobic drugs.